EIGR Eiger BioPharmaceuticals Inc.

11.86
-0.02  -0%
Previous Close 11.88
Open 11.9
Price To Book 3.29
Market Cap 290,511,257
Shares 24,495,047
Volume 124,670
Short Ratio
Av. Daily Volume 128,433
Stock charts supplied by TradingView

NewsSee all news

  1. Eiger to Present at Jefferies 2019 London Healthcare Conference

    PALO ALTO, Calif., Nov. 15, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today

  2. Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019

    PALO ALTO, Calif., Nov. 12, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted, first-in-class therapies for serious rare and ultra-rare

  3. Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

    PALO ALTO, Calif., Nov. 7, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today

  4. Eiger to Present at Cantor 2019 Global Healthcare Conference

    PALO ALTO, Calif., Sept. 27, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today

  5. Eiger BioPharmaceuticals to Participate in September Conferences

    PALO ALTO, Calif., Aug. 29, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data released October 16, 2018 - endpoints met. Data presented at ENDO March 25, 2019.
Avexitide (Exendin 9-39)
Post-Bariatric Hypoglycemia (PBH)
Phase 2 LIMT data noted 36% curable virologic response at 24 weeks post-treatment - April 11. 2019.
Pegylated Interferon Lambda (LIMT HDV)
Hepatitis delta virus (HDV)
Phase 3 enrolment to be completed by the end of 2019.
Lonafarnib - D-LIVR
Chronic hepatitis delta virus (HDV)
Phase 2 trial did not meet endpoints - January 16, 2018.
Ubenimex - LIBERTY
Pulmonary arterial hypertension (PAH)
Phase 2 data released October 16, 2018 did not meet endpoints.
Ubenimex - ULTRA
Secondary lymphedema
Phase 2b negative data released April 2015. Formerly CLDN pre-merger
MYDICAR - CUPID 2 Trial
Ischemic or dilated cardiomyopathy
Phase 2 data presented at AASLD November 12, 2019 - Median HDV RNA decline was 3.4 log IU/mL (IQR: 2.9-4.5, p<0.0001).
Pegylated interferon lambda + ritonavir (RTV)-boosted lonafarnib (LNF) - LIFT
Hepatitis delta virus (HDV)
NDA filing due 4Q 2019.
Lonafarnib
Hutchinson-Gilford Progeria Syndrome (HGPS)

Latest News

  1. Eiger to Present at Jefferies 2019 London Healthcare Conference

    PALO ALTO, Calif., Nov. 15, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today

  2. Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019

    PALO ALTO, Calif., Nov. 12, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted, first-in-class therapies for serious rare and ultra-rare

  3. Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

    PALO ALTO, Calif., Nov. 7, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today

  4. Eiger to Present at Cantor 2019 Global Healthcare Conference

    PALO ALTO, Calif., Sept. 27, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today

  5. Eiger BioPharmaceuticals to Participate in September Conferences

    PALO ALTO, Calif., Aug. 29, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today